SYNOPSIS

On

“A STUDY OF FINANCIAL PERFORMNACE OF CIPLA AND

AUROBINDO PHARMA PVT. LTD.”

Submitted by
RASIKA A. KHAPREY

Under the Guidance of

PROF. ANJALI CHANDAK

Submitted in partial fulfillment for the award of the degree

of
MASTER OF BUSINESS ADMINISTRATION

DEPARTMENT OF MANAGEMENT STUDIES

J D COLLEGE OF ENGINEERING AND MANAGEMENT

RASHTRASANT TUKADOJI MAHARAJ NAGPUR UNIVERSITY
NAGPUR
SESSION: 2018 – 2019
 INDEX

SR. NO. CHAPTER NAME PAGE NO.

1 INTRODUCTION

2 COMPANY PROFILE

3 OBJECTIVES OF THE STUDY

4 HYPOTHESIS

5 SCOPE OF THE STUDY

6 RESEARCH METHODOLOGY

7 BIBLIOGRAPHY
 INTRODUCTION

Financial Performance

The level of performance of a business over a specified period of time,

expressed in terms of overall profits and losses during that time. Evaluating the
financial performance of a business allows decision-makers to judge
the results of business strategies and objective activities in monetary terms.

After liberalization the Indian banking sector developed very appreciate.

The RBI also nationalized good amount of commercial banks for proving socio
economic services to the people of the nation. The Indian banking sector has
shown very good performance as far as the financial operations are concerned.
If we look to the glance of the financial operations, we may find that deposits of
banks have been increased. The total incomes of the banks have also shown
good performance since the last few years. The gross profit and the net profit
also increased very rapidly.

In this era of liberalization, Privatization and globalization banking sector

has become backbone of Indian economy now a day’s banking sector being an
integral part of Indian financial system has undergone dramatic changes
reflecting the ongoing economic and financial sector reforms. Banking sector
has playing vital role in development of Indian agriculture and industries. At
presently Banking has become Important part of economy & society. Banking
industry which was highly regulated in pre-reform period is reorienting itself to
face new challenges emerging in the financial sector globally. Basis factors
responsible for performance of public sectors banks were stringent regulation,
poor recovery process and above all lack of competition.
 COMPANY PROFILE

Cipla Limited is an Indian multinational pharmaceutical and

biotechnology company, headquartered in Mumbai, India. Cipla primarily
develops medicines treat respiratory, cardiovascular disease, arthritis, diabetes
weight control and depression; other medical conditions.

It was founded by Khwaja Abdul Hamied as 'The Chemical, Industrial

& Pharmaceutical Laboratories' in 1935 in Mumbai. The name of the Company
was changed to 'Cipla Limited' on 20 July 1984. In the year 1985, US FDA
approved the company's bulk drug manufacturing facilities. Led by the
founder’s son Yusuf Hamied, a Cambridge-educated chemist, the company
provided generic AIDS and other drugs to treat poor people in the developing
world. In 1995, Cipla launched Deferiprone, the world’s first oral iron chelator.
In 2001, Cipla offered medicines (antiretrovirals) for HIV treatment at a
fractional cost (less than $350 per year per patient).

In 2013 Cipla acquired the South African company Cipla-Medpro, kept it

as a subsidiary, and changed its name to Cipla Medpro South Africa Limited. At
the time of the acquisition Cipla-Medpro had been a distribution partner for
Cipla and was South Africa's third biggest pharmaceutical company. The
company had been founded in 2002 and was known as Enaleni Pharmaceuticals
Ltd. In 2005, Enaleni bought all the shares of Cipla-Medpro, which had been a
joint venture between Cipla and Medpro Pharmaceuticals, a South African
generics company, and in 2008 it changed its name to Cipla-Medpro.
 Aurobindo Pharma Limited (APL), one of the world’s top 5
manufacturers of semi synthetic penicillin’s was incorporated in 26th
December 1986 as a private limited company. Mr. P.V.Ramaprasad Reddy,
Mr. K.Nityananda Reddy and a small, highly committed group of
professionals founded it. APL is developing, manufacturing and marketing
active pharmaceutical ingredients (APIs also referred as bulk actives),
intermediates and generic formulations. The company’s robust product
portfolio is spread over 6 major product areas encompassing (Antibiotics,
Anti-Retro Virals, CVS, CNS, Gastroenterological, and Anti-Allergics) with
around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic
segment and the World Health Organization (WHO), Geneva, has also
approved Aurobindo’s products. APL is running with 14 manufacturing
plants across the world conforming to GMP/ISO regulations and an
extremely well equipped R&D facility. Aurobindo Pharma has identified
international operations also catering to over 100 countries.

The Company has accelerated the DMF/ANDA filings programme in

its efforts to build a broad product portfolio for the regulated markets.
Cumulatively, the Company has filed a total of 337 DMFs (Drug Master
Files), of which 110 are with US FDA, and 133 in Europe including with the
EDQM and 102 in other countries.
 OBJECTIVES OF THE STUDY

 To study of financial policies of both the Cipla and Aurobindo Pharma.

 To measure the impact of financial performance on the market value of
Cipla and Aurobindo Pharma.
 To know about financial position of Cipla and Aurobindo Pharma.
 To analyze the financial performance.
 To know about the capital structure of Cipla and Aurobindo Pharma.
 HYPOTHESIS

H0 (Null Hypothesis) :-

Cipla financial position is relatively strong compared to Aurobindo

Pharma in respect with its income and Assets, Cipla is relatively better than the
Aurobindo Pharma.

H1 (Alternate Hypothesis) :-

Aurobind Pharma financial position is relatively strong compared to

Cipla in respect with its income and Assets, Aurobind Pharma is relatively
better than the Cipla Pharma.
 SCOPE OF STUDY

The study is confined to the financial management of Aurobindo

Pharmacy and cipla Pharmacy of various component in financial statements.
The study is analysis of all the available components of ratio analysis and to
make item wise analysis of the financial statements.
 RESEARCH METHODOLOGY

Research methodology is an important tool in any research work. It acts as guideline

and road in completion of research. It is scientific search for data and information on as
particular topic research is search for knowledge.

Research methodology is a way to systematically solve the research problem. It may

be understood as a science of studying now research is done systematically. In that various
steps, those are generally adopted by a researcher in studying his problem along with the
logic behind them. It is important for research to know not only the research method but also
know methodology.

DATA COLLECTION

There are several ways of collecting the appropriate data which differ considerably in
context of money, cost, time and other sources at the disposable of the researcher. These are
two types of data.

1. Primary Data
2. Secondary Data
Primary Data:-

Primary data are those which are collected afresh and for the first time, and thus
happen to be original in character. In case of descriptive research, researcher performs survey
whether sample survey or census survey, thus we obtain primary data either through

Secondary Data:-

Secondary data are those which have already been collected by someone else and
have already been passed through statistical process. In this project report, both types of data
have been used. Mainly, secondary data is used such as annual reports.

 Annual Reports
 Internet
 Company journal
 Various books
 BIBLIOGRAPHY

1. I.M.Pandey : Financial management

2. M.Y.Khan & P.K.Jai : Financial Management

3. S.P. Jain & K.L. Narang : Cost & Management A/c

4. K.Rajeswara rao & G. Prasad : Accounting & Finance

5. P.Kulakarni : Financial Management

Web-sites:

 www.google.com
 www.aurobindopharmacy.com
 www.ciplapharma.com
 www.wikipedia.com